期刊文献+

盐酸文拉法辛亲水/蜡质骨架缓释片的制备及其释药特性研究

Preparation and Release Characteristics of Venlafaxine Hydrochloride Hydrophilic and Lipidic Matrix Sustained-release Tablets
下载PDF
导出
摘要 目的:制备盐酸文拉法辛亲水/蜡质骨架缓释片,考察其释药特性。方法:以山嵛酸甘油酯作为蜡质骨架、羟丙甲纤维素(HPMC)作为亲水凝胶骨架,通过单因素试验筛选辅料种类及用量;以4、8、24 h的累积释放量与理想值偏差之和作为评价指标,采用正交试验优化HPMC黏度、HPMC K15M用量和山嵛酸甘油酯用量,并通过不同方程拟合释放曲线。结果:最优处方为盐酸文拉法辛8.5 kg,HPMC K15M 15 kg,山嵛酸甘油酯26 kg,硬脂酸镁0.5 kg;所制骨架缓释片4、8、24 h的累积释放度分别为34.3%、63.9%、99.2%;体外释药符合一级释药特征,以骨架溶蚀机制为主。结论:成功制得缓释效果良好的盐酸文拉法辛亲水/蜡质骨架缓释片。 OBJECTIVE:To prepare Venlafaxine hydrochloride sustained-release tablets,and to investigate the characteristics of drug release. METHODS:Using glyceryl behenate as lipidic matrix material and HPMC as hydrophilic matrix material,the kind and dosage of excipients were screened by single factor experiment. Using 4,8,24 h accumulative release rate and the deviation summation of ideal values as index,the viscosity of HPMC,the amounts of HPMC K15 M and glyceryl behenate were optimized by orthogonal test. The dissolution curves were fitted by different equations. RESULTS:The optimal formulation was as follows as venlafaxine hydrochloride 8.5 kg,HPMC K15 M 15 kg,glyceryl behenate 26 kg,magnesium stearate 0.5 kg. 4,8,24 h accumulative release rates of prepared matrix sustained-release tablets were 34.3%,63.9% and 99.2%,respectively. The releases profiles of hydrophilic and lipidic matrix sustained release tablets followed first-order equation in vitro mainly through matrix erosion. CONCLUSIONS:Venlafaxine hydrochloride hydrophilic and lipidic matrix sustained-release tablets with good sustained-release effect have been prepared successfully.
出处 《中国药房》 CAS 北大核心 2016年第22期3109-3111,共3页 China Pharmacy
基金 国家科技重大专项课题(No.2012ZX0940-1004)
关键词 盐酸文拉法辛 亲水/蜡质骨架缓释片 羟丙甲纤维素 山嵛酸甘油酯 Venlafaxine hydrochloride Hydrophilic and lipidic matrix sustained-release tablets Hydroxypropyl methylcellu-lose Glyceryl behenate
  • 相关文献

参考文献7

二级参考文献48

  • 1董志超,蒋雪涛.羟丙基甲基纤维素在凝胶骨架中的含量与水溶性药物释放机制的关系[J].药学学报,1996,31(1):43-47. 被引量:31
  • 2钟历勇,王孝蓉,赵志刚.二甲双胍缓释片的临床优势[J].实用糖尿病杂志,2006,2(4):54-56. 被引量:3
  • 3李一云,屠鉴源,季建林.文拉法辛缓释剂与速释剂临床对照分析[J].临床精神医学杂志,2007,17(1):34-35. 被引量:2
  • 4Famaey JP. In vitro and in vivo pharmacological evidence of selective cyclooxygenase-2 inhibition by nimesulide: An overview[J]. Inflamm Res, 1997, 46( 11 ) : 437.
  • 5Salvi GE, Lang NP. The effects of non-steroidal anti-infl- ammatory drugs (selective and non-selective) on the treatment of periodontal diseases[J]. Curr Pharm Des, 2005, 11(14):1 757.
  • 6Blanchi M, Broggini M. A randomized, double blind, clinical trial comparing the efficacy of nimesulide, celecoxib and rofecoxid in osteoarthritis of the knee[J]. Drugs, 2003, 63(63) :37.
  • 7Zhang Y, Huo M, Zhou J, et al. DDSolver. An add-in program for modeling and comparison of drug dissolution profiles[J].AAPSJ, 2010, 12(3): 263.
  • 8MADHUSUDAN R Y, VENI J K, JAYASAGAR G. Formulation and evaluation of diclofenac sodium using hydrophilic matrices [ J ]. Drug Dev Ind Pharm, 2001,27 (8) :759-766.
  • 9ZHANG Yue, SCHWARTZ J B. Meh granulation and heat treatment for wax matrix-controlled drug release [ J ]. Drug Dev lnd Pharm,2003,29(2) : 131 - 138.
  • 10VUEBA M L, BATISTA de CARVALHO L A E, VEIGA F, et al. Influence of cellulose ether polymers on ketoprofen release from hydrophilic matrix tablets [ J ]. Eur J Pharm Biopharm,2004,58( 1 ) :51 -59.

共引文献34

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部